全文获取类型
收费全文 | 6542篇 |
免费 | 392篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 163篇 |
妇产科学 | 140篇 |
基础医学 | 1029篇 |
口腔科学 | 134篇 |
临床医学 | 470篇 |
内科学 | 1654篇 |
皮肤病学 | 264篇 |
神经病学 | 572篇 |
特种医学 | 167篇 |
外科学 | 583篇 |
综合类 | 29篇 |
预防医学 | 299篇 |
眼科学 | 160篇 |
药学 | 521篇 |
中国医学 | 24篇 |
肿瘤学 | 685篇 |
出版年
2024年 | 4篇 |
2023年 | 44篇 |
2022年 | 111篇 |
2021年 | 172篇 |
2020年 | 96篇 |
2019年 | 181篇 |
2018年 | 172篇 |
2017年 | 142篇 |
2016年 | 165篇 |
2015年 | 176篇 |
2014年 | 242篇 |
2013年 | 292篇 |
2012年 | 496篇 |
2011年 | 504篇 |
2010年 | 287篇 |
2009年 | 253篇 |
2008年 | 410篇 |
2007年 | 471篇 |
2006年 | 478篇 |
2005年 | 479篇 |
2004年 | 439篇 |
2003年 | 384篇 |
2002年 | 399篇 |
2001年 | 58篇 |
2000年 | 36篇 |
1999年 | 50篇 |
1998年 | 77篇 |
1997年 | 58篇 |
1996年 | 50篇 |
1995年 | 36篇 |
1994年 | 40篇 |
1993年 | 29篇 |
1992年 | 17篇 |
1991年 | 24篇 |
1990年 | 15篇 |
1989年 | 14篇 |
1988年 | 11篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 8篇 |
1976年 | 2篇 |
1974年 | 3篇 |
1972年 | 2篇 |
1969年 | 4篇 |
1968年 | 2篇 |
排序方式: 共有6973条查询结果,搜索用时 6 毫秒
71.
72.
We developed a simple and sustainable method for the hydroxy-perfluoroalkylation of electron-deficient conjugated olefins and styrenes. In this protcol, in situ generated enamine forms electron-donor–accepter (EDA) complexes with perfluoroalkyl iodide, and reaction proceed with visible-light irradiation. Tertiary amine also interacts with perfluoroalkyl iodide via halogen-bonding, promoting the perfluoroalkyl radical generation. This reaction does not require any transition-metal or photoredox catalyst, and gaseous oxygen is used as the green hydroxy source. Moreover, various commercially available substrates and perfluoroalkyl iodides were tolerated, affording the desired hydroxy-perfluoroalkylated products in good to moderate yields (>50 examples, up to 90%).A sustainable, visible-light-induced hydroxy-perfluoroalkylation of electron-deficient olefins and styrenes catalyzed by ena mine were successfully developed. 相似文献
73.
Hitoshi Tanaka Hisanori Hattori Tomoko Oh-Uchi Masaru Sato Ryozo Yamaguchi Magoichi Sako 《Journal of Asian natural products research》2013,15(10):983-987
Two new isoflavanones, 5,3′-dihydroxy-4′-methoxy-5′-(3-methyl-1,3-butadienyl)-2″,2″-dimethylpyrano[5,6:6,7]isoflavanone (1) and 5,3′-dihydroxy-5′-(3-hydroxy-3-methyl-1-butenyl)-4′-methoxy-2″,2″-dimethylpyrano[5,6:6,7]isoflavanone (2), together with two known isoflavonoids, cristacarpin, and euchrenone b10, were isolated from the stems of Erythrina costaricensis. Their structures were established on the basis of spectroscopic evidence. These new compounds are rare isoflavanones, possessing both a 2,2-dimethylpyran substituent and a prenyl analog. The antibacterial activities of 1 and 2 against the methicillin-resistant Staphylococcus aureus were examined. 相似文献
74.
Long‐term clinical outcomes of testicular sperm extraction and intracytoplasmic sperm injection for infertile men 下载免费PDF全文
75.
Naruhiko Ishiwada Nobuyuki Takada Tomoko Okunushi Haruka Hishiki Harutaka Katano Noriko Nakajima Yoichi Kohno 《Pediatrics international》2012,54(5):703-705
The influenza A/H1N1 2009 epidemic has spread to many countries since 2009, including Japan. We report an immune‐competent child involving rhabdomyolysis and compartment syndrome associated with influenza A/H1N1 2009. The patient was demonstrated rhabdomyolysis with myoglobinuria, hyperkalemia, cardiac dysfunction and compartment syndrome that arose during convalescence from influenza A/H1N1 2009 infection. Although RT‐PCR of muscle tissue yielded negative results for influenza A/H1N1 2009 RNA and no viral positive‐antigen cells were detected in the muscle lesions, the clinical picture suggested rhabdomyolysis associated with influenza A/H1N1. Rhabdomyolysis should be considered in the evaluation of muscle symptoms such as myalgia associated with novel influenza A/H1N1 2009 virus infection, particularly in critically ill patients. 相似文献
76.
Haruhisa Kato Makiko Naito Tomoko Saito Takuto Hideyama Yasuhiro Suzuki Takashi Kimura Shin Kwak Hitoshi Aizawa 《JOURNAL OF CLINICAL NEUROLOGY》2022,18(4):463
Background and PurposeAmyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease. Selective deficiency of edited adenosine deaminase acting on RNA 2 (ADAR2), a key molecule in the acquisition of Ca2+ resistance in motor neurons, has been reported in sporadic ALS (sALS) spinal motor neurons. Since ADAR2 activity is positively regulated by prolyl isomerase Protein never in mitosis gene A interacting-1 (Pin1), a known phosphorylation-dependent peptidyl-prolyl cis/trans isomerase, we investigated Pin1 expression in spinal motor neurons in sALS.MethodsSpecimens of the spinal cord were obtained from the lumbar region in eight sALS patients and age-matched five controls after postmortem examinations. The specimens were double stained with anti-Pin1 and anti-TAR DNA-binding protein of 43 kDa (TDP-43) antibodies, and examined under a fluorescence microscope.ResultsThis study analyzed 254 and 422 spinal motor neurons from 8 sALS patients and 5 control subjects, respectively. The frequency of motor neurons with high cytoplasmic Pin1 expression from the spinal cord did not differ significantly between sALS specimens without cytoplasmic TDP-43 inclusions and control specimens. However, in sALS specimens, neurons for which the Pin1 immunoluminescence intensity in the cytoplasm was at least twice that in the background were more common in specimens with cytoplasmic TDP-43 inclusions (p<0.05 in χ2 test).ConclusionsIn sALS, neurons with higher expression levels of Pin1 levels had more TDP-43 inclusions. Despite the feedback mechanism between Pin1 and ADAR2 being unclear, since Pin1 positively regulates ADAR2, our results suggest that higher Pin1 expression levels in motor neurons with TDP-43 pathology from sALS patients represent a compensatory mechanism. 相似文献
77.
Hisato Shima Toshio Doi Takuya Okamoto Yusuke Higashiguchi Megumi Harada Tomoko Inoue Manabu Tashiro Seiichiro Wariishi Norimichi Takamatsu Kazuhiko Kawahara Kazuyoshi Okada Jun Minakuchi 《Internal medicine (Tokyo, Japan)》2022,61(12):1863
A 39-year-old woman was hospitalized for nephrotic syndrome. Laboratory test results showed increased serum creatinine levels and urinary excretions of beta-2-microglobulin, and N-acetyl-beta-D-glucosaminidase. A renal biopsy revealed collapsing focal segmental glomerulosclerosis (FSGS) and acute interstitial nephritis. Despite treatment with pulse steroid followed by oral high-dose glucocorticoids and cyclosporines, heavy proteinuria persisted. After low-density lipoprotein apheresis (LDL-A) therapy was initiated, her proteinuria gradually decreased, leading to complete remission. A repeat renal biopsy after treatment revealed no collapsing glomeruli. Immediate LDL-A should be performed to treat cases of collapsing FSGS poorly responding to other treatments. 相似文献
78.
Kenichi Shikata Sadayoshi Ito Naoki Kashihara Masaomi Nangaku Takashi Wada Yasuyuki Okuda Tomoko Sawanobori Kotaro Sugimoto 《Journal of diabetes investigation.》2022,13(7):1190
Aims/IntroductionWe evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum potassium elevation in Japanese patients with diabetic kidney disease.Materials and MethodsWe carried out a prespecified subanalysis of data from two phase III studies: a multicenter, randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes and microalbuminuria (J308); and a multicenter, single‐arm, open‐label trial in patients with type 2 diabetes and macroalbuminuria (J309). Changes in serum potassium levels during the studies and other measures were evaluated according to SGLT2 inhibitor use.ResultsIn both studies, time‐course changes in serum potassium levels, and incidence rates of serum potassium elevation were lower in patients with co‐administration of SGLT2 inhibitor in both the placebo and esaxerenone groups than those without the inhibitor. In contrast, time‐course changes and mean percentage changes from baseline in urinary albumin‐to‐creatinine ratio, the proportion of patients with albuminuria remission and time‐course changes in blood pressure did not change with or without SGLT2 inhibitor, whereas the albumin‐to‐creatinine ratio and blood pressure were reduced with esaxerenone. The blood glucose‐lowering effect of SGLT2 inhibitor was not affected by esaxerenone.ConclusionsIn Japanese patients with type 2 diabetes and albuminuria treated with esaxerenone, concomitant use of SGLT2 inhibitor reduced the magnitude of serum potassium elevation without any change of its antihypertensive and albuminuria‐suppressing effects. Co‐administration of esaxerenone and SGLT2 inhibitor might be a beneficial treatment option for patients with diabetic kidney disease. 相似文献
79.
Tomoko Akahane Kenta Masuda Akira Hirasawa Yusuke Kobayashi Arisa Ueki Miho Kawaida Kumiko Misu Kohei Nakamura Shimpei Nagai Tatsuyuki Chiyoda Wataru Yamagami Shigenori Hayashi Fumio Kataoka Kouji Banno Kokichi Sugano Hajime Okita Kenjiro Kosaki Hiroshi Nishihara Daisuke Aoki 《Journal Of Gynecologic Oncology》2022,33(4)
ObjectivePrecursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of high-grade serous carcinoma, whereas the significance of the p53 signature remains unclear. In this study, we investigated the relationship between the p53 signature and the risk of ovarian cancer.MethodsWe analyzed the clinicopathological findings and conducted DNA sequencing for TP53 variants of p53 signatures and STIC lesions isolated using laser capture microdissection in 13 patients with pathogenic variants of BRCA1/2 who underwent RRSO and 17 control patients with the benign gynecologic disease.Results TP53 pathogenic variants were detected significantly higher in RRSO group than control (p<0.001). No difference in the frequency of p53 signatures were observed between groups (53.8% vs 29.4%; p=0.17). TP53 sequencing and next-generation sequencing analysis in a patient with STIC and occult cancer revealed 2 TP53 mutations causing different p53 staining for STICs and another TP53 mutation shared between STIC and occult cancer.ConclusionThe sequence analysis for TP53 revealed 2 types of p53 signatures, one with a risk of progression to STIC and ovarian cancer with pathological variants in TP53 and the other with a low risk of progression without pathological variants in TP53 as seen in control. 相似文献
80.
Kensei Yamaguchi Keiko Minashi Daisuke Sakai Tomohiro Nishina Yasushi Omuro Masahiro Tsuda Shiroh Iwagami Hisato Kawakami Taito Esaki Naotoshi Sugimoto Takashi Oshima Ken Kato Kenji Amagai Hisashi Hosaka Keigo Komine Hisateru Yasui Yuji Negoro Kenji Ishido Takahiro Tsushima Shirong Han Shinichi Shiratori Tomoko Takami Kohei Shitara 《Cancer science》2022,113(8):2814
The KEYNOTE‐659 study evaluated the efficacy and safety of first‐line pembrolizumab plus S‐1 and oxaliplatin (SOX) (cohort 1) or S‐1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the results of cohort 2. This open‐label phase IIb study enrolled patients with advanced programmed death‐ligand 1 (PD‐L1)‐positive (combined positive score ≥ 1) human epidermal growth factor receptor 2 (HER2)‐negative G/GEJ adenocarcinoma. The primary end‐point was the objective response rate (ORR). Other end‐points were duration of response (DOR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and safety. One hundred patients were enrolled. In cohorts 1 and 2, median follow‐up time was 16.9 and 17.1 months; ORR (central review), 72.2% and 80.4%; DOR, 10.6 and 9.5 months; DCR (central review), 96.3% and 97.8%; median PFS (central review), 9.4 and 8.3 months; and median OS, 16.9 and 17.1 months, respectively. Treatment‐related adverse events (TRAEs) occurred in all patients, including peripheral sensory neuropathy (94.4%, cohort 1), decreased neutrophil count (82.6%, cohort 2), nausea (59.3% and 60.9% in cohorts 1 and 2), and decreased appetite (61.1% and 60.9% in cohorts 1 and 2). Grade 3 or higher TRAEs were reported by 59.3% (cohort 1) and 78.3% (cohort 2), including decreased platelet count (14.8%, cohort 1) and decreased neutrophil count (52.2%, cohort 2). Pembrolizumab in combination with SOX or SP showed favorable efficacy and safety in patients with PD‐L1‐positive, HER2‐negative G/GEJ adenocarcinoma. 相似文献